3.4 Preferred Stock Protective Provisions. At any time when any shares of Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, recapitalization, reclassification or otherwise, do any of the following without (in addition to any other vote required by law or this Amended and Restated Certificate of Incorporation) the written consent or affirmative vote of the Preferred Majority given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect:
3.4.1 alter or change the rights, preferences or privileges of the Preferred Stock or any series thereof;
3.4.2 liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, or consent to any of the foregoing;
3.4.3 amend, alter or repeal any provision of this Amended and Restated Certificate of Incorporation or Bylaws of the Corporation;
3.4.4 (i) create, or authorize the creation of, including by way of reclassifying, altering or amending any existing security of the Corporation, any additional class or series of capital stock unless the same ranks junior to the Preferred Stock or any series thereof with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, provided, that, if the actions or transactions of the Corporation covered by this Section 3.4.4 are not approved by the Series B Director, then solely for purposes of this provision, the “Preferred Majority” must include Series B Financial Investors holding at least 2,400,000 shares of Series B Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock) (the “Requisite Series B Financial Investors Approval”). For purposes of this Amended and Restated Certificate of Incorporation, “Series B Financial Investors” means investors who hold Series B Preferred Stock that were received in exchange for Series B preferred membership units of Metagenomi Technologies, LLC, acquired pursuant to that certain Series B Purchase Agreement, dated as of January 21, 2022, by and among the Corporation and the other purchasers party thereto (as may be amended from time to time, the “Series B Purchase Agreement”), excluding (i) holders who also hold shares of Series A Preferred Stock and (ii) ModernaTX, Inc. and its Affiliates (as defined in the Series B Purchase Agreement);
3.4.5 increase or decrease the authorized number of shares of Common Stock or Preferred Stock or any series thereof;
3.4.6 purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation other than (i) redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock, (iii) repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service pursuant to the terms of the applicable purchase or grant agreement at no greater than the original purchase price thereof or (iv) the exercise of a contractual right of first refusal entitling the Corporation or a subsidiary to purchase shares as approved by the Board of Directors;